EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Licochalcone A suppresses pancreatic ductal adenocarcinoma progression by targeting eEF2K-mediated pyroptosis

Junjie Peng, Hiutung Chan, Wenqing Chen, Ken Kin-Lam Yung, King-Ho Cheung, Zhu Zhang

Frontiers in Pharmacology · 11.06.2025 · 16

DOI: 10.3389/fphar.2025.1595686 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.06.2025. Verfasst von Junjie Peng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Teaching and Research Division, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC), a highly aggressive malignancy with increasing incidence and low survival rates, urgently requires novel therapeutic strategies to overcome the limitations posed by current treatment agents like gemcitabine. Licochalcone A (LHA), a bioactive flavonoid derived from Glycyrrhiza species, exhibits anticancer properties in multiple cancers, yet its efficacy and mechanisms in PDAC remain unexplored. This study aims to investigate the anticancer potential of LHA in PDAC. In vitro assays demonstrated that LHA dose-dependently inhibited PDAC cell proliferation and induced pyroptosis, a lytic inflammatory cell death, while autophagy inhibition synergistically enhanced the cytotoxicity of LHA. Furthermore, LHA suppressed the migration of PDAC cells. Mechanistically, molecular docking and functional studies revealed that LHA directly binds to eukaryotic elongation factor 2 kinase (eEF2K), reducing its expression and downstream phosphorylation of eukaryotic elongation factor 2 (p-eEF2). Notably, eEF2K overexpression reversed LHA-induced pyroptosis in PDAC cells. In vivo , LHA significantly reduced tumor growth and altered tumor histopathology in a PDAC xenograft model, along with downregulated eEF2K and upregulated pyroptosis executors (GSDMD/GSDME). Collectively, these findings identify LHA as a dual-function agent: a natural eEF2K inhibitor and a pyroptosis inducer with potent antitumor activity against PDAC. This study provides a foundational rationale for further clinical exploration of LHA as a promising chemotherapeutic agent or adjuvant to enhance PDAC treatment outcomes.

Schlagwörter

Stichwörter der Autor:innen

autophagyeEF2Klicochalcone Apancreatic ductal adenocarcinomapyroptosis

Autor:innen und Institutionen

  • Teaching and Research Division, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, China.
  • Department of Science and Environmental Studies, The Education University of Hong Kong, Tai Po, Hong Kong SAR, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Peng, J., Chan, H., Chen, W., Yung, K. K., Cheung, K. H., & Zhang, Z. (2025). Licochalcone A suppresses pancreatic ductal adenocarcinoma progression by targeting eEF2K-mediated pyroptosis. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1595686

Vancouver

Peng J, Chan H, Chen W, Yung KK, Cheung KH, Zhang Z. Licochalcone A suppresses pancreatic ductal adenocarcinoma progression by targeting eEF2K-mediated pyroptosis. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1595686

BibTeX
@article{Peng2025,
  author = {Peng, Junjie and Chan, Hiutung and Chen, Wenqing and Yung, Ken Kin-Lam and Cheung, King-Ho and Zhang, Zhu},
  title = {Licochalcone A suppresses pancreatic ductal adenocarcinoma progression by targeting eEF2K-mediated pyroptosis},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1595686}
}
Kostenlos starten →